The Johnson & Johnson patent-infringement suit against Boston Scientific Corp. went to a jury Monday, after closing arguments that focused on the importance of cardiac-stent technology at stake in the case. Gregory Diskant, attorney for New Brunswick, N.J.-based J&J, said the groundbreaking invention of stenting technology, which keeps treated arteries open, "revolutionized cardiology." John Desmarais, attorney for Natick, Mass.-based Boston Scientific, told the eight jurors set to begin weighing charges of patent infringement that the Taxus Express stent - one of the devices on which J&J claims patent infringement - is "the most important cardiovascular stenting product in the world." Court papers say J&J is seeking $844 million in lost profits from Boston Scientific on the grounds it has taken market share with stents that infringe the landmark patent obtained by Julio Palmaz, the Texas doctor credited with inventing the idea to leave tiny metal scaffolds in clogged arteries.

Posted by GEN-ERIC at 12:11:56 am into the following categories: In The News

---

http://gen-eric.com/patents/htsrv/trackback.php/271

Name:

Email: (not displayed on this site)

Site/Url:

Comment text:

Allowed XHTML tags: <p, ul, ol, li, dl, dt, dd, address, blockquote, ins, del, a, span, bdo, br, em, strong, dfn, code, samp, kdb, var, cite, abbr, acronym, q, sub, sup, tt, i, b, big, small>

URLs, email, AIM and ICQs will be converted automatically.

Options:
Auto-BR (Line breaks become <br />)
Remember me (Set cookies for name, email & url)